With the US generic cycle turning back for the better, and Strides turning EBITBA positive again, how do you equate Strides to your other headwind buys like Avanti and Globus, from a risk-reward perspective, given that valuations are at rock bottom and optionality is whatever they manage to do with Stelis?
| Subscribe To Our Free Newsletter |
